Tags

Type your tag names separated by a space and hit enter

Pitfalls in the detection of CV2 (CRMP5) antibodies.
J Neuroimmunol. 2016 Jan 15; 290:80-3.JN

Abstract

CV2 antibodies (CV2-ab) associate with paraneoplastic neurological syndromes (PNS) and small-cell lung cancer. This study was designed to assess the sensitivity of two widely used anti-CV2 commercial kits. Fifty three sera with CV2-ab identified by immunohistochemistry on paraformaldehyde-perfused rat brain were tested with two commercial immunoblot kits (Euroimmun AG, and Ravo Diagnostika) and 4 (7.5%) of them were negative with the commercial kits. The 4 samples were positive by immunofluorescence on HEK293 cells transfected with CRMP5 and immunoblot of these cells lysate. A few CV2-ab-positive sera may be missed by commercial immunoblots. Negative samples from patients with high suspicion for PNS should be tested by alternative methods.

Authors+Show Affiliations

Neuroimmunology Program, Institut d'Investigació Biomèdica August Pi i Sunyer (IDIBAPS), Barcelona, Spain.Neuroimmunology Program, Institut d'Investigació Biomèdica August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Service of Neurology, Hospital Clinic, University of Barcelona, Spain.Neuroimmunology Program, Institut d'Investigació Biomèdica August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Institució Catalana de Recerca i Estudis Avançats (ICREA), Barcelona, Spain; Department of Neurology, University of Pennsylvania, Philadelphia, USA.Neuroimmunology Program, Institut d'Investigació Biomèdica August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Service of Neurology, Hospital Clinic, University of Barcelona, Spain. Electronic address: fgraus@clinic.ub.es.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

26711575

Citation

Sabater, Lidia, et al. "Pitfalls in the Detection of CV2 (CRMP5) Antibodies." Journal of Neuroimmunology, vol. 290, 2016, pp. 80-3.
Sabater L, Saiz A, Dalmau J, et al. Pitfalls in the detection of CV2 (CRMP5) antibodies. J Neuroimmunol. 2016;290:80-3.
Sabater, L., Saiz, A., Dalmau, J., & Graus, F. (2016). Pitfalls in the detection of CV2 (CRMP5) antibodies. Journal of Neuroimmunology, 290, 80-3. https://doi.org/10.1016/j.jneuroim.2015.11.009
Sabater L, et al. Pitfalls in the Detection of CV2 (CRMP5) Antibodies. J Neuroimmunol. 2016 Jan 15;290:80-3. PubMed PMID: 26711575.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Pitfalls in the detection of CV2 (CRMP5) antibodies. AU - Sabater,Lidia, AU - Saiz,Albert, AU - Dalmau,Josep, AU - Graus,Francesc, Y1 - 2015/12/01/ PY - 2015/10/28/received PY - 2015/11/12/revised PY - 2015/11/15/accepted PY - 2015/12/30/entrez PY - 2015/12/30/pubmed PY - 2016/4/28/medline KW - CV2 (CRMP5) antibodies KW - Cancer KW - Immunoblot KW - Paraneoplastic SP - 80 EP - 3 JF - Journal of neuroimmunology JO - J. Neuroimmunol. VL - 290 N2 - CV2 antibodies (CV2-ab) associate with paraneoplastic neurological syndromes (PNS) and small-cell lung cancer. This study was designed to assess the sensitivity of two widely used anti-CV2 commercial kits. Fifty three sera with CV2-ab identified by immunohistochemistry on paraformaldehyde-perfused rat brain were tested with two commercial immunoblot kits (Euroimmun AG, and Ravo Diagnostika) and 4 (7.5%) of them were negative with the commercial kits. The 4 samples were positive by immunofluorescence on HEK293 cells transfected with CRMP5 and immunoblot of these cells lysate. A few CV2-ab-positive sera may be missed by commercial immunoblots. Negative samples from patients with high suspicion for PNS should be tested by alternative methods. SN - 1872-8421 UR - https://www.unboundmedicine.com/medline/citation/26711575/Pitfalls_in_the_detection_of_CV2__CRMP5__antibodies_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0165-5728(15)30076-X DB - PRIME DP - Unbound Medicine ER -